OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 33
Showing 1-25 of 33 citing articles:
Enhancing panvascular medicine: unveiling the nexus of pan-cardio-oncology and expanding therapeutic frontiers
Yiqing Hu, You Zhou, Neng Dai, et al.
Science Bulletin (2025)
Closed Access | Times Cited: 3
Yiqing Hu, You Zhou, Neng Dai, et al.
Science Bulletin (2025)
Closed Access | Times Cited: 3
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114172-114172
Closed Access | Times Cited: 10
Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, et al.
European Journal of Cancer (2024) Vol. 207, pp. 114172-114172
Closed Access | Times Cited: 10
Gut microbiome and immune checkpoint inhibitor toxicity
Rik J. Verheijden, Mick J M van Eijs, Fernanda L. Paganelli, et al.
European Journal of Cancer (2025) Vol. 216, pp. 115221-115221
Closed Access | Times Cited: 1
Rik J. Verheijden, Mick J M van Eijs, Fernanda L. Paganelli, et al.
European Journal of Cancer (2025) Vol. 216, pp. 115221-115221
Closed Access | Times Cited: 1
Manganese Galvanic Cells Intervene in Tumor Metabolism to Reinforce cGAS‐STING Activation for Bidirectional Synergistic Hydrogen‐Immunotherapy
Nailin Yang, Shumin Sun, Jiachen Xu, et al.
Advanced Materials (2025)
Closed Access | Times Cited: 1
Nailin Yang, Shumin Sun, Jiachen Xu, et al.
Advanced Materials (2025)
Closed Access | Times Cited: 1
Self-Cascaded Pyroptosis-STING Initiators for Catalytic Metalloimmunotherapy
Qiao Yu, Shumin Sun, Nailin Yang, et al.
Journal of the American Chemical Society (2025)
Closed Access | Times Cited: 1
Qiao Yu, Shumin Sun, Nailin Yang, et al.
Journal of the American Chemical Society (2025)
Closed Access | Times Cited: 1
A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks
Mark Schuiveling, Hong Liu, Daniel Eek, et al.
GigaScience (2025) Vol. 14
Open Access | Times Cited: 1
Mark Schuiveling, Hong Liu, Daniel Eek, et al.
GigaScience (2025) Vol. 14
Open Access | Times Cited: 1
Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells
Matthieu Paiola, Daniel M Portnoy, Luke Hao, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010758-e010758
Open Access | Times Cited: 1
Matthieu Paiola, Daniel M Portnoy, Luke Hao, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010758-e010758
Open Access | Times Cited: 1
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective
Yang Xiao, Yongsheng Li, Huakan Zhao
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Yang Xiao, Yongsheng Li, Huakan Zhao
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy
Nežka Hribernik, Katja Strašek, Andrej Studen, et al.
Radiology and Oncology (2025) Vol. 59, Iss. 1, pp. 43-53
Open Access
Nežka Hribernik, Katja Strašek, Andrej Studen, et al.
Radiology and Oncology (2025) Vol. 59, Iss. 1, pp. 43-53
Open Access
Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review
Le Zhang, Siyuan Fan, Jiawei Wang, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Closed Access
Le Zhang, Siyuan Fan, Jiawei Wang, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Closed Access
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy
Qiongjie Hu, Yueli Shi, Huang Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Qiongjie Hu, Yueli Shi, Huang Wang, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Immune-related adverse events are associated with better event-free survival in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer
Alejandro Ríos-Hoyo, Jiawei Dai, Tony Noël, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104494-104494
Closed Access
Alejandro Ríos-Hoyo, Jiawei Dai, Tony Noël, et al.
ESMO Open (2025) Vol. 10, Iss. 4, pp. 104494-104494
Closed Access
Pharmacogenomic variants in the Pumi population from Yunnan, China
Xiao Yang, Yujing Cheng, Qi Li, et al.
Gene (2025), pp. 149421-149421
Closed Access
Xiao Yang, Yujing Cheng, Qi Li, et al.
Gene (2025), pp. 149421-149421
Closed Access
Autoimmune-related adverse events induced by immune checkpoint inhibitors
Yini Sun, Ziyang Zhang, Jia Ke, et al.
Current Opinion in Immunology (2025) Vol. 94, pp. 102556-102556
Closed Access
Yini Sun, Ziyang Zhang, Jia Ke, et al.
Current Opinion in Immunology (2025) Vol. 94, pp. 102556-102556
Closed Access
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
Chaoqi Zhang, Peng Wu, Dongyu Li, et al.
Med (2025), pp. 100669-100669
Closed Access
Chaoqi Zhang, Peng Wu, Dongyu Li, et al.
Med (2025), pp. 100669-100669
Closed Access
Immunotherapy for Thymomas and Thymic Carcinomas: Current Status and Future Directions
Arun Rajan, Alisa K. Sivapiromrat, Meredith J. McAdams
Cancers (2024) Vol. 16, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 3
Arun Rajan, Alisa K. Sivapiromrat, Meredith J. McAdams
Cancers (2024) Vol. 16, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 3
Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
Emma Titmuss, Irene Yu, Erin Pleasance, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 1865-1875
Open Access | Times Cited: 1
Emma Titmuss, Irene Yu, Erin Pleasance, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 1865-1875
Open Access | Times Cited: 1
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial
Ruixi Wang, Yihong Ling, Baoqing Chen, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102806-102806
Open Access | Times Cited: 1
Ruixi Wang, Yihong Ling, Baoqing Chen, et al.
EClinicalMedicine (2024) Vol. 75, pp. 102806-102806
Open Access | Times Cited: 1
Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase
Roberta Noseda, Francesca Bedussi, Valentina Giunchi, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009902-e009902
Open Access | Times Cited: 1
Roberta Noseda, Francesca Bedussi, Valentina Giunchi, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009902-e009902
Open Access | Times Cited: 1
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
Evangelos Triantafyllou, Cathrin Gudd, Lucia Possamai
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Evangelos Triantafyllou, Cathrin Gudd, Lucia Possamai
Nature Reviews Gastroenterology & Hepatology (2024)
Closed Access | Times Cited: 1
Enhancing antitumor response by efficiently generating large-scale TCR-T cells targeting a single epitope across multiple cancer antigens
Obed Boadi Amissah, Rajesh Basnet, Wenfang Chen, et al.
Cellular Immunology (2024) Vol. 399-400, pp. 104827-104827
Closed Access
Obed Boadi Amissah, Rajesh Basnet, Wenfang Chen, et al.
Cellular Immunology (2024) Vol. 399-400, pp. 104827-104827
Closed Access
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
Isabella A.J. van Duin, Mark Schuiveling, Laurens S. ter Maat, et al.
Immuno-Oncology Technology (2024) Vol. 24, pp. 100714-100714
Open Access
Isabella A.J. van Duin, Mark Schuiveling, Laurens S. ter Maat, et al.
Immuno-Oncology Technology (2024) Vol. 24, pp. 100714-100714
Open Access
Engineered CARD11–PIK3R3 T‐cell therapies as weapons of cancer mass destruction
Wanlu Zhang, Min Wu, Yongye Huang
MedComm (2024) Vol. 5, Iss. 7
Open Access
Wanlu Zhang, Min Wu, Yongye Huang
MedComm (2024) Vol. 5, Iss. 7
Open Access
Updates and emerging trends in the management of immune-related adverse events associated with immune checkpoint inhibitor therapy
Ninh M. La‐Beck, Jesuwapelumi Owoso
Asia-Pacific Journal of Oncology Nursing (2024) Vol. 11, Iss. 9, pp. 100549-100549
Open Access
Ninh M. La‐Beck, Jesuwapelumi Owoso
Asia-Pacific Journal of Oncology Nursing (2024) Vol. 11, Iss. 9, pp. 100549-100549
Open Access
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients
Laura M. Timmerman, Lobke C.M. Hensen, Mick J M van Eijs, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 9
Open Access
Laura M. Timmerman, Lobke C.M. Hensen, Mick J M van Eijs, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 9
Open Access
